Alimera Sciences, Inc. (ALIM) recently announced that it has entered into a definitive agreement with Minnesota-based biopharmaceutical company, ANI Pharmaceuticals, Inc. (ANIP) , wherein the latter has agreed to acquire Alimera.Shares of Alimera shot up 75.9% on Jun 24 following the news announcement, while ANIP shares rose 7.3%.Per the deal terms, Alimera is set to be acquired by ANIP for $5.50 per share in cash and its investors will be entitled to a contingent value right for up to $0.50 per share if ce ...

MILWAUKEE, June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals.Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.In the transaction, Alimera public shareholders will receive only $5.50 per share in cash at closing and one non-tradable contingent valu ...

Alimera Sciences (NASDAQ:ALIM) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ:ANIP).This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock. It also includes contingent rights of 50 cents per share. These are payable if certain revenue goals are met in 2026 and 2027.Investors in Alimera Sciences will note that this offer is a 75% premium to ALIM stock’s prior closing price. It’s also an 82% premiu ...

Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.ANI shares are roughly flat at writing.  Alimera Sciences stock valued at a 75% premiumCopy link to sectionANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has als ...

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to ...

ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the "Compensation Comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (Stat ...

财务数据和关键指标变化 - 公司2024年第一季度合并全球净收入同比增长70%至2300万美元,主要由于收购YUTIQ和全球终端用户需求增长23% [13] - 公司2024年第一季度实现正的调整后EBITDA 180万美元,而2023年同期为EBITDA亏损240万美元 [14] - 公司重申有信心实现2024年105亿美元收入和至少20%的调整后EBITDA利润率 [14] 各条业务线数据和关键指标变化 - 美国业务2024年第一季度净收入增长92%至1460万美元,主要由于收购YUTIQ [16] - 美国终端用户需求增长96%,包括YUTIQ,单独计算ILUVIEN和YUTIQ则增长2% [16] - 国际业务2024年第一季度净收入增长42%至850万美元,主要由于直接市场需求增长53%和分销商订货增长72% [21][31][32] 各个市场数据和关键指标变化 - 英国NICE发布最终指南,建议将ILUVIEN用于治疗慢性糖尿病黄斑水肿引起的视力损害,不论患者是否已做白内障手术 [21][22] - 这将扩大ILUVIEN在英国的潜在患者群,因为非手术白内障患者占整个糖尿病黄斑水肿患者的75% [22] - 这一NICE决定如果在其他市场如西班牙和意大利得到采纳,也将扩大ILUVIEN在这些国家的潜在患者群 [23] 公司战略和发展方向及行业竞争 - 公司正在优化ILUVIEN和YUTIQ的销售信息,强调疾病严重程度与视网膜厚度波动的关系 [19][20] - 公司正在实施一项非临床价值计划,为更多使用ILUVIEN和YUTIQ的医生提供回报 [50][53] - 公司参与DRCR视网膜网络的协议AL研究,评估ILUVIEN与抗VEGF注射在放射性视网膜病变预防中的作用 [26][27] 管理层对经营环境和未来前景的评论 - 公司对2024年的发展前景保持信心,预计收入和利润率将随季节性波动 [15][36] - 公司认为ILUVIEN在国际市场的成功增长是ILUVIEN和YUTIQ在美国市场的领先指标 [40][41] - 公司相信NEW DAY研究和Synchronicity研究将支持ILUVIEN和YUTIQ在DME和葡萄膜炎治疗中的应用 [42] 问答环节重要的提问和回答 问题1 **Chase Knickerbocker 提问** 医生是否了解ILUVIEN和YUTIQ在两种适应症上的使用,公司如何优化销售信息传达 [45][46][47][48] **Rick Eiswirth 和 Todd Wood 回答** 公司正在进行教育宣传,帮助医生了解ILUVIEN和YUTIQ在不同慢性炎症性眼病中的应用 [46][47][48] 问题2 **Yi Chen 提问** 公司是否需要为DRCR协议AL研究提供资金支持 [58][59][60][61] **Rick Eiswirth 回答** 公司将在4-5年内提供约125万美元的研究资金支持 [61] 问题3 **Naz Rahman 提问** 英国NICE决定对ILUVIEN的影响,以及对公司毛利的影响 [71][72][73][74] **Rick Eiswirth 和 Philip Ashman 回答** 这一决定不会直接影响价格,但有望扩大ILUVIEN在英国的使用量,从而提高收入 [72][73][74]

Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this eye drug developer would post earnings of $0.02 per share when it actually produced a loss of $0.07, delivering a surprise of -450%.Over the last four quarters, the company ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2024 Results · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced fi ...